Want to see IN:TARSONS full AI Analyst Report?
TARSONS Stock Chart & Stats
₹230.25
-₹6.55(-1.58%)
At close: 4:00 PM EST
₹230.25
-₹6.55(-1.58%)
Day’s Range― - ―
52-Week Range₹164.15 - ₹405.30
Previous CloseN/A
Volume39.72K
Average Volume (3M)2.32K
Market Cap
₹14.12B
Enterprise Value₹18.47B
Total Cash (Recent Filing)₹252.56M
Total Debt (Recent Filing)₹3.93B
Price to Earnings (P/E)98.2
Beta1.03
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.86%
Share Statistics
EPS (TTM)2.70
Shares Outstanding53,206,280
10 Day Avg. Volume1,556
30 Day Avg. Volume2,322
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables BusinessTarsons’ core business supplies frequently replenished lab consumables (pipette tips, tubes, cultureware). That replacement-driven demand creates predictable, high-frequency reorder cycles and customer stickiness across diagnostics, pharma and academia, supporting durable revenue visibility and channel leverage.
Positive Operating Cash FlowImproving, positive operating cash flow indicates the underlying business converts sales into cash despite earnings volatility. Over 2–6 months this supports working capital, funds ongoing operations, and reduces immediate liquidity pressure, enabling reinvestment or gradual deleveraging if sustained.
Revenue Pickup And Continued ProfitabilityA 2026 revenue pickup, together with ongoing profitability, suggests demand recovery after uneven prior years. If this trend persists it can underpin margin stabilization, better capacity utilization and improved returns, helping restore efficiency lost during the 2023–2025 downturn.
Bears Say
Rising LeverageA sharp increase in debt over multiple years raises solvency and refinancing risk. Higher leverage amplifies earnings volatility, increases fixed interest costs, and reduces strategic flexibility. If earnings or cash flow fail to recover, debt servicing could constrain investment and raise default risk over the medium term.
Persistent Negative Free Cash FlowOngoing negative free cash flow implies capex or working capital outlays exceed operating cash generation, forcing reliance on external financing or asset sales. Over several years this can erode liquidity, raise funding costs, and limit returns to shareholders unless operating cash conversion improves materially.
Deteriorating Profitability And Compressed ROEMaterial margin and earnings decline, plus compressed ROE, indicate weakening profitability and lower capital efficiency. This reduces the company’s ability to self-fund growth, absorb cost shocks, and justify higher leverage, posing a persistent headwind to long-term value creation unless margins recover.
Tarsons Products Limited News
TARSONS FAQ
What was Tarsons Products Limited’s price range in the past 12 months?
Tarsons Products Limited lowest stock price was ₹164.15 and its highest was ₹405.30 in the past 12 months.
What is Tarsons Products Limited’s market cap?
Tarsons Products Limited’s market cap is ₹14.12B.
When is Tarsons Products Limited’s upcoming earnings report date?
Tarsons Products Limited’s upcoming earnings report date is Aug 19, 2026 which is in 45 days.
How were Tarsons Products Limited’s earnings last quarter?
Tarsons Products Limited released its earnings results on May 22, 2026. The company reported ₹0.79 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.79.
Is Tarsons Products Limited overvalued?
According to Wall Street analysts Tarsons Products Limited’s price is currently Overvalued.
Does Tarsons Products Limited pay dividends?
Tarsons Products Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.86%. See more information on Tarsons Products Limited dividends here
What is Tarsons Products Limited’s EPS estimate?
Tarsons Products Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tarsons Products Limited have?
Tarsons Products Limited has 53,206,280 shares outstanding.
What happened to Tarsons Products Limited’s price movement after its last earnings report?
Tarsons Products Limited reported an EPS of ₹0.79 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.83%.
Which hedge fund is a major shareholder of Tarsons Products Limited?
Currently, no hedge funds are holding shares in IN:TARSONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tarsons Products Limited
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features disposable plastic labware, centrifuge and cryogenic equipment, liquid handling systems, and safety products. Its comprehensive catalog further encompasses items such as bottles, carboys, measuring cylinders, cell culture products, electrophoresis apparatus, microscopy and microbiology tools, vacuum desiccators, mini coolers, cryo boxes, beakers, test tube racks, pipette tips, petri dishes, centrifuge tubes, cryogenic and storage vials, Pasteur pipettes, and vortex mixers, among many others. These offerings are vital for research and applications across various scientific disciplines including molecular biology, cell culture, genomics, proteomics, and immunology.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Poly Medicure Limited
―
Vimta Labs Limited
―
Zim Laboratories Ltd.
―
Fischer Medical Ventures Ltd
―